Neogen Recalls HYCOAT Vials After Microbial Contamination; Q2 Revenue Falls 2.8%
Neogen Corporation has voluntarily recalled all within-expiry lots of its HYCOAT Hyaluronate Sodium Sterile Solution (10 mL/50 mg and 2 mL/20 mg vials) due to microbial contamination and reported equine adverse events. In Q2 2026, the company posted $224.7 million revenue (down 2.8% YOY), a $15.9 million net loss and $22.6 million adjusted net income.
1. Voluntary HYCOAT Recall
Neogen issued a voluntary recall of all within-expiry lots of its HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats and horses after detecting microbial contamination in certain 10 mL/50 mg vials and reporting adverse equine reactions, prompting inclusion of 2 mL/20 mg vials out of caution.
2. Q2 2026 Financial Results
In fiscal second quarter 2026, Neogen recorded $224.7 million in revenue, a 2.8% year-over-year decline, while core growth rose 2.9%. The company reported a net loss of $15.9 million alongside an adjusted net income of $22.6 million.
3. FDA Collaboration and Ongoing Investigation
Management is conducting a root-cause investigation into the contamination and is proactively collaborating with the FDA to strengthen safety controls and guide remediation efforts within its Animal Safety segment.